Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Blood ; 123(12): 1836-49, 2014 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-24452203

RESUMEN

Splenic marginal zone lymphoma (SMZL) is a mature B-cell neoplasm characterized by rather indolent clinical course. However, nearly one third of patients experience a rapidly progressive disease with a dismal outcome. Despite the characterization of clone genetics and the recognition of deregulated immunologic stimulation in the pathogenesis of SMZL, little is known about microenvironment dynamics and their potential biological influence on disease outcome. Here we investigate the effect of stroma-intrinsic features on SMZL disease progression by focusing on the microenvironment of the bone marrow (BM), which represents an elective disease localization endorsing diagnostic and prognostic relevance. We show that the quality of the BM stromal meshwork of SMZL infiltrates correlates with time to progression. In particular, we describe the unfavorable prognostic influence of dense CD40 expression by BM stromal cells, which involves the contribution of CD40 ligand (CD40L)-expressing bystander mast cells infiltrating SMZL BM aggregates. The CD40/CD40L-assisted crosstalk between mesenchymal stromal cells and mast cells populating the SMZL microenvironment finds correlation in p53(-/-) mice developing SMZL and contributes to the engendering of detrimental proinflammatory conditions. Our study highlights a dynamic interaction, playing between nonneoplastic elements within the SMZL niche, toward disease progression.


Asunto(s)
Antígenos CD40/metabolismo , Linfoma de Células B de la Zona Marginal/inmunología , Linfoma de Células B de la Zona Marginal/patología , Mastocitos/inmunología , Mastocitos/patología , Células Madre Mesenquimatosas/inmunología , Células Madre Mesenquimatosas/patología , Adulto , Anciano , Anciano de 80 o más Años , Animales , Linfocitos B/inmunología , Linfocitos B/patología , Ligando de CD40/metabolismo , Diferenciación Celular , Proliferación Celular , Citocinas/biosíntesis , Progresión de la Enfermedad , Supervivencia sin Enfermedad , Femenino , Genes p53 , Humanos , Mediadores de Inflamación/metabolismo , Linfoma de Células B de la Zona Marginal/etiología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Noqueados , Persona de Mediana Edad , Pronóstico , Microambiente Tumoral/inmunología
2.
Leuk Lymphoma ; 55(11): 2457-65, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24506469

RESUMEN

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoid neoplasms characterized by aggressive clinical behavior and dismal prognosis. Hepatosplenic γδ T-cell lymphoma (γδ-HSTL) is a particular form of PTCL that arises from a small subset of γ/δ T-cell receptor-expressing lymphocytes. γδ-HSTL has a rapidly progressive course and poor outcome due also to its refractoriness to conventional chemotherapy regimens. The very low incidence of γδ-HSTL, along with its propensity to mimic different pathological entities, makes this lymphoma a true diagnostic challenge. In this review, we highlight the biological and clinical features of γδ-HSTL that contribute to making this lymphoma a mostly incurable disease. Moreover, we provide a new insight into the crosstalk between HSTL clones and the bone marrow, liver and spleen vascular microenvironment, in which neoplastic cells reside and proliferate. We further discuss γδ-HSTL associated molecules that might be proposed as potential targets for novel therapeutic approaches.


Asunto(s)
Neoplasias Hepáticas/patología , Linfoma de Células T Periférico/patología , Receptores de Antígenos de Linfocitos T gamma-delta/metabolismo , Neoplasias del Bazo/patología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Terapia Combinada , Humanos , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/terapia , Linfoma de Células T Periférico/metabolismo , Linfoma de Células T Periférico/terapia , Neoplasias del Bazo/metabolismo , Neoplasias del Bazo/terapia , Trasplante de Células Madre/métodos , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA